RedHill Biopharma Shares Surge New Treatment Patent For Its Late-Stage COVID-19 Candidate

  • The United States Patent and Trademark Office (USPTO) granted a further method of use patent for RedHill Biopharma Ltd's RDHL COVID-19 treatment, opaganib.
  • The move grants a new method of use patent to inhibit COVID-19 in patients with pneumonia and receiving supplemental oxygen at a fraction of inspired oxygen (FiO2) up to and including 60%.
  • The new patent, expiring in 2041, protects the results from a post-hoc analysis from the global Phase 2/3 study in hospitalized patients with COVID-19 pneumonia.
  • Related: RedHill Biopharma Says Its Oral Broad-Acting Antivirals Inhibit Dominant Omicron Sub-Variant BA.5.
  • In the analysis of 251 participants requiring a FiO2 up to and including 60% at baseline (54% of study participants), oral opaganib resulted in a 62% reduction in mortality, improved outcomes in time to room air and median time to hospital discharge, and a reduced likelihood of intubation and mechanical ventilation.
  • Late-stage development of opaganib is ongoing pending Phase 3 trial design regulatory approvals and securing of external funding.
  • Price Action: RDHL shares are up 50.90% at $0.70 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!